Okogen to receive over $10mn from MRCF through Series A funding

Date: 2018-03-01   Author: Saipriya Iyer  Category: #market

Okogen to receive over $10mn from MRCF through Series A funding

Brandon Capital’s Medical Research Commercialization Fund (MRCF), one of the biggest life science investment fund firms in New Zealand & Australia, has reportedly made investments worth USD 10 million in Okogen Inc., a biotech firm developing ophthalmic anti-effective medicines, in its Series A funding. As per sources, the funds are expected to assist Okogen in developing OKG 0301, a leading candidate for viral conjunctivitis.

For the uninitiated, adenoviral conjunctivitis is one of the main causes of eye infection across the globe. With no approved treatments, unmet medical needs of patients are rampant across the globe. Researchers have been testing the ability of OKG-0301, an effective ribonuclease with proven antiviral characteristics, to treat viral conjunctivitis in the patients by conducting Phase 2 clinical trials before 2018.

Incidentally, OKG-0301 is currently undergoing clinical development, and with MRCF’s funds, the commencement of the Phase II clinical trial for OKG-0301 will be onboard in 2018. As per reports, nearly 30 million cases of acute conjunctivitis occur yearly across the globe, which includes approximately 6 million of the U.S. population. Around 70% of the U.S. population is treated for acute conjunctivitis every year, and 80% of these patients are diagnosed with viral forms of the infection.

The CEO of Okogen Inc., has announced that safe & effective therapies are required to treat highly infectious ailments such as conjunctivitis and OKG-0301 has the clinical & commercial potential to treat the same. He further added that the Series A funding by Brandon Capital will help the firm in exploring new opportunities across the biopharmaceutical sector.

MRCF’s Investment Manager has also reaffirmed his faith in Okogen by stating that the funding will help in making Okogen’s technology stronger and equip the same with the potential of bringing a positive change in the lives of many patients.



About Author


Saipriya Iyer linkdin-boxtwitter

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

Post Recommendents

Abiogen Pharma takes over Altamedics in a deal worth $8 million

Author: Pankaj Singh

Italy-based pharmaceutical company Abiogen Pharma S.p.A. has reportedly completed the acquisition of Altamedics GmbH, a German pharmaceutical distribution company, which is slated to become the first foreign branch of ...


Healthcare Gamification Market Share, Size, Technology Advancement, Top Companies, Forecast 2027

Author: Rahul Varpe

DEC Research has published its most recent report with the title ‘Global Healthcare Gamification Market In-depth Research on Industry Size, Trends, Emerging Growth Factors to 2027’. The report basically contains an outline of the Healt...


Medical Gloves Market Share, Growth, Technology Advancements, and Forecast by 2030

Author: Rahul Varpe

DEC Research has published its most recent report with the title ‘Global Medical Gloves Market In-depth Research on Industry Size, Trends, Emerging Growth Factors to 2030’. The report basically contains an outline of the Medical Gloves...